The company intends to divest Roctavian and “remove it from our portfolio,” CEO Alexander Hardy said, following nearly three ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

Clearance of Lynkuet provides a new alternative to hormone-based treatment for hot flashes and sets up a market battle with ...

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...

For biopharma, reaching the right patients at the right time is essential for both clinical and commercial success. The right ...

The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation ...

The deal, which Novartis expects can “unlock multibillion-dollar opportunities” in the years ahead, hands the company a group ...

The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.

Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...

The French pharma’s overall vaccine sales declined 8% in the quarter, with a key driver being slower-than-usual uptake of flu ...

Chugai is acquiring partial rights to a marketed IgA nephropathy drug. Elsewhere, ICER claimed Americans are often ...

The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...